Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Kobe Bryant called this WNBA star the 'Gold Mamba.' She turned his advice to her into a tattoo. - 2Vote In favor of Your Favored Menial helper Administration
- 3'War is not over': Detailed diagrams of prisons found in cells of Oct. 7 terrorists
- 4Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered.
- 5Winter solstice 2025 marks the shortest day of the year in the Northern Hemisphere today
- Warning for snow and ice extended
- Figure out How to Consolidate Cutting edge innovations in Senior's SUVs
- Grammy nominations 2026: Full list of nominees in every major category, including Album of the Year and Best New Artist
- How Mars 'punches above its weight' to influence Earth's climate
- The Manual for Well known rough terrain Vehicles
- 7 Logically Demonstrated Techniques for Better Rest
- How did this 20-light-year-wide 'Diamond Ring' form in space? Maybe a cosmic bubble burst
- Step by step instructions to Think about Disc Rates Across Various Banks
- She loves to give experiences. He goes for sentimental gifts. They ask an expert: What is the perfect holiday present?
